Thermo Fisher Scientific (NYSE:TMO), a leading life sciences company, announced its financial results for the first quarter of calendar year 2025, reporting revenue of $10.36 billion. This figure met analysts’ estimates and was unchanged compared to the same quarter last year, signaling stable performance despite market headwinds.
The company also reported a non-GAAP earnings per share (EPS) of $5.15, slightly exceeding Wall Street expectations by 0.9%. While the earnings beat was modest, it reflects Thermo Fisher’s ability to maintain profitability in a flat revenue environment.
Following the earnings announcement and investor call, Thermo Fisher’s stock remained steady, closing at $433.50. The lack of significant price movement suggests that the results were largely in line with investor expectations.
Thermo Fisher is known for providing products and services in scientific research, healthcare, and diagnostics. The company’s ability to maintain its revenue base amid broader industry challenges is seen as a sign of operational resilience.
The financial performance in Q1 2025 sets the stage for the company’s ongoing strategies focused on innovation and acquisition-led growth in the life sciences sector.
Source: https:// – Courtesy of the original publisher.
